Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Liaoning Chengda Biotechnology Co Days Payable Chart
SHSE:688739 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Liaoning Chengda Biotechnology Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Liaoning Chengda Biotechnology Co Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Liaoning Chengda Biotechnology Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Liaoning Chengda Biotechnology Co's Days Payable falls into.
Liaoning Chengda Biotechnology Co Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Liaoning Chengda Biotechnology Co (SHSE:688739) has a Days Payable of 200.18 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Liaoning Chengda Biotechnology Co and its competitors. This is 21% above median its historical median of 164.78. Over the past decade, Liaoning Chengda Biotechnology Co's Days Payable has ranged from 14.79 to 298.06. According to the industry distribution chart, Liaoning Chengda Biotechnology Co ranks #218 out of 701 companies in the Biotechnology industry, placing it in the top 31.1%.
Is Liaoning Chengda Biotechnology Co's Days Payable too high?
Liaoning Chengda Biotechnology Co's current Days Payable of 200.18 is 21% above median its 10-year median of 164.78. Over the past 10 years, this metric has ranged from a low of 14.79 to a high of 298.06. The Biotechnology industry median Days Payable is 112.84. Liaoning Chengda Biotechnology Co's value of 200.18 is 77.4% above this industry median. Based on the distribution chart, Liaoning Chengda Biotechnology Co ranks #218 out of 701 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Liaoning Chengda Biotechnology Co has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Liaoning Chengda Biotechnology Co's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Liaoning Chengda Biotechnology Co ranks #218 out of 701 companies for Days Payable. This puts Liaoning Chengda Biotechnology Co in the upper half of its industry. The industry median Days Payable is 112.84. Liaoning Chengda Biotechnology Co's value of 200.18 is 77.4% above this benchmark. Historically, Liaoning Chengda Biotechnology Co's own Days Payable has ranged from 14.79 to 298.06 over the past decade. While the company's 10-year median is 164.78 vs. the industry median of 112.84, Liaoning Chengda Biotechnology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Liaoning Chengda Biotechnology Co's current Days Payable of 200.18 is 77.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Liaoning Chengda Biotechnology Co and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Liaoning Chengda Biotechnology Co's current Days Payable is 200.18, which is 21% above median its own 10-year median of 164.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Liaoning Chengda Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, Liaoning Chengda Biotechnology Co (SHSE:688739) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥22.10, compared to a current price of ¥19.98 — trading 9.6% below its estimated fair value. The current Days Payable is 200.18, which is 21% above median its 10-year median of 164.78 and 77.4% above the Biotechnology industry median of 112.84. Liaoning Chengda Biotechnology Co's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Liaoning Chengda Biotechnology Co (SHSE:688739), the current Days Payable is 200.18 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Liaoning Chengda Biotechnology Co (SHSE:688739) Overvalued in 2026?
Based on GuruFocus' analysis, Liaoning Chengda Biotechnology Co stock appears to be undervalued.
The current stock price of ¥19.98 is trading 9.6% below its estimated GF Value™ of ¥22.10.
GuruFocus considers Liaoning Chengda Biotechnology Co to be Modestly Undervalued.
Key valuation signals for SHSE:688739:
Days Payable: 200.18 (21% above median its 10-year median of 164.78)
GF Value™: ¥22.10 vs. price of ¥19.98 (9.6% below fair value)
Industry Position: 77.4% above the Biotechnology median (#218 of 701)
No single metric tells the full story. See the SHSE:688739 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Liaoning Chengda Biotechnology Co Business Description
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688739 has been successfully added to your 
